Kevin Patrick Danahy - 23 Oct 2023 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role
Chief Executive Officer
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Issuer symbol
PLSE
Transactions as of
23 Oct 2023
Net transactions value
$0
Form type
4
Filing time
03 Nov 2023, 17:41:33 UTC
Previous filing
14 Jul 2023
Next filing
17 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Stock Option (right to buy) Award $0 +130,000 $0.000000 130,000 23 Oct 2023 Common Stock 130,000 $3.96 Direct F1
transaction PLSE Stock Option (right to buy) Other $0 -130,000 -100% $0.000000* 0 01 Nov 2023 Common Stock 130,000 $3.96 Direct F1, F2
transaction PLSE Stock Option (right to buy) Award $0 +460,000 $0.000000 460,000 01 Nov 2023 Common Stock 460,000 $4.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares will vest in four equal annual installments on each of the first four annual anniversaries of the grant date, subject to the Reporting Person's continued service through each vesting date.
F2 Reporting Person was erroneously granted an option to acquire 130,000 shares on October 23, 2023, which option was cancelled by mutual agreement on November 1, 2023.
F3 100% vesting upon the earlier of (i) the six (6) year anniversary of the grant date, and (ii) the 1-year anniversary of a Company change of control.